Skip to main content

Shark Tank



I love Shark Tank. I think I've mentioned that before, even on this blog. Indeed, now that I've checked ... I wrote a post here that discussed the structure of the show. Today, I'll say something about the personalities.

Kevin O'Leary is the hostile stereotype of a capitalist, come to life and played at least somewhat for laughs. When Kevin decides that he has no use for a particular entrepreneur, he says "you';re dead to me." Not "I'm out" (the phrasing shared by all the other sharks in the same situation) but "you're dead to me."

Yet there is sometimes a "tough love" aspect to Kevin's snarkiness. I remember an episode in which two young men, who could not or would not offer many business plan specifics, were trying to sell equity in their computer password-protection system. Kevin (and Mark Cuban as well, IIRC) were interrupting them with hostile or sarcastic seeming questions. The two ladies on the panel, Lori Greiner and Barbara Corcoran, were trying to throw them lifelines, and criticizing Kevin's harshness.

But ... as the presentation would down, Lori and Barbara declared themselves out. Kevin was the last shark still "in" and the only one who offered them a deal.

The point? If you want someone to invest in you, you may have to perfect your shit-eating grin.

The two men with the password protection system turned down Kevin's offer, and exited the tank with their heads held high but sans working capital.

Comments

Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.



We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

Hume's Cutlery

David Hume is renowned for two pieces of cutlery, the guillotine and the fork.

Hume's guillotine is the sharp cut he makes between "is" statements and "ought" statements, to make the point that the former never ground the latter.

His "fork" is the division between what later came to be called "analytic" and "synthetic" statements, with the ominous observation that any books containing statements that cannot be assigned to one or the other prong should be burnt.

Actually, I should acknowledge that there is some dispute as to how well or poorly the dichotomy Hume outlines really maps onto the analytic/synthetic dichotomy. Some writers maintain that Hume meant something quite different and has been hijacked. Personally, I've never seen the alleged difference however hard they've worked to point it out to me.

The guillotine makes for a more dramatic graphic than a mere fork, hence the bit of clip art above.

I'm curious whe…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…